



Stock Market Indexes	Last	Change	1 Month	YTD	1 Year
Indonesia - JCI	6,382.94	▲ 2.00%	▲ 7.57%	▲ 6.75%	▲ 1.73%
Indonesia - LQ45	1,001.02	▲ 2.22%	▲ 7.37%	▲ 7.07%	▼ -1.56%
Indonesia - JII	671.15	▲ 0.62%	▲ 6.77%	▲ 6.46%	▼ -2.92%
US - Dow Jones	31,008.69	▼ -0.29%	▲ 3.13%	▲ 1.31%	▲ 7.09%
Europe - Stoxx 600	408.41	▼ -0.67%	▲ 3.42%	▲ 2.35%	▼ -2.68%
Asia ex. Japan - MFEJ	841.02	▼ -0.30%	▲ 8.00%	▲ 5.12%	▲ 27.32%
Hong Kong - Hang Seng	27,908.22	▲ 0.11%	▲ 5.30%	▲ 2.49%	▼ -2.29%
Malaysia - KLCI	1,617.25	▼ -0.98%	▼ -1.78%	▼ -0.61%	▲ 1.35%
Philippines - PCOMP	7,304.79	▲ 0.20%	▲ 2.85%	▲ 2.56%	▼ -6.32%
Singapore - STI	2,983.90	▼ -0.31%	▲ 4.95%	▲ 4.93%	▼ -8.12%
South Korea - KOSPI	3,148.45	▼ -0.12%	▲ 14.26%	▲ 9.57%	▲ 44.00%
Taiwan - TWSE	15,557.30	▲ 0.60%	▲ 8.11%	▲ 5.60%	▲ 29.96%
Thailand - SET	1,536.49	▲ 0.00%	▲ 3.63%	▲ 5.77%	▼ -2.73%
Bond Index					
IBPA Indonesia Government Bond Total Return Index	339.74	▼ -0.21%	▲ 0.54%	▼ -0.89%	▲ 13.05%
Exchange Rate					
USD-IDR	14,125.00	▼ -0.75%	▼ -0.14%	▼ -1.66%	▼ -1.96%

Source: Bloomberg. Data based on closing date T-1, and on "change" compared to T-2. During holiday, data will use next working date.



BPOM Issues Permit for Emergency Use of Sinovac Vaccines

CoronaVac, as the Covid-19 vaccine produced by the Sinovac company, has officially obtained an emergency use permit or EUA from the Food and Drug Administration (BPOM) of the Republic of Indonesia. "The CoronaVac vaccine meets the requirements to get EUA," said Head of BPOM Penny K Lukito in an online press conference monitored from Jakarta, Monday (11/1). She said, in deciding to grant the emergency authorization, BPOM considered the results of clinical trials in Indonesia, Brazil and Turkey, which showed that the SARS-CoV-2 antiviral had safety and efficacy (efficacy) in preventing Covid-19. In addition, she said, the Sinovac vaccine meets World Health Organization (WHO) standards for obtaining EUA approval with an efficacy level of at least 50%. She said, BPOM and related stakeholders continue to monitor the vaccination process, especially the side effects of the Sinovac vaccine.

Investor Daily

BI: Consumer Confidence Index for December 2020 Strengthens to 96.5

Bank Indonesia reports that consumer confidence has improved again in December 2020. Based on a BI consumer survey, this can be seen from the Consumer Confidence Index (IKK) at the end of last year which was at the level of 96.5. This realization increased from the IKK in November 2020 which was in the position of 92.0. In December 2020, the IKK experienced an increase in all categories of respondents' expenditure levels, especially respondents with an expenditure of Rp. 4.1 million to Rp. 5 million per month. Meanwhile, from the age group, the increase in CCI also occurred in the majority of age groups, especially respondents aged 20-30 years. The improvement in consumer confidence in December 2020 was driven by stronger perceptions of current economic conditions and expectations for the future. On the other hand, the Economic Condition Index (IKE) also rose to 68.6, from 60.1 in the previous month.

Kontan

Highest Number of Covid-19 Cases in Seven Weeks, France Considering Lockdown

The number of new Covid-19 infections in France has increased by more than 18,000 cases per day on average, the highest in seven weeks. Meanwhile, the number of people hospitalized has risen as France grapples with a more contagious variant of the virus, which was first discovered in Britain. The latest trend, published on Monday, will be discussed in the coming days by the government considering whether to impose a third national lockdown and extend the extension of the 6pm curfew starting at 6pm on Tuesday. Several regions, throughout France. French authorities have identified three more cases of the more contagious variant of Covid-19 that is now spreading in Britain, according to a report by regional newspaper Ouest France late Monday, citing health officials.

Kontan

Disclaimer : This document is made only as public information, and on specific investment target, individuals specific preference and allocation has not included in this document. You don't have to depend on this document as investment recommendation. If you have interest of anything about investment product, or if you do not have confidence on investment decision, you have to search financial recommendation from your professional advisor. Information that provided in this document are from trustable source, however, Allianz does not guarantee data accuracy. Opinion or prediction can be changed without any prior information, and for that Allianz strictly refuse each and every responsibility on statement and guarantation, imply or not imply, stated in here or not stated.